Hanover - Delayed Quote • EUR
Swedish Orphan Biovitrum AB (B6E.HA)
At close: April 26 at 9:06 AM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,140,000.00
22,123,000.00
18,790,000.00
15,529,000.00
15,261,000.00
Cost of Revenue
5,477,000.00
4,995,000.00
4,776,000.00
3,484,000.00
3,225,000.00
Gross Profit
17,663,000.00
17,128,000.00
14,014,000.00
12,045,000.00
12,036,000.00
Operating Expense
13,664,000.00
12,948,000.00
10,169,000.00
8,258,000.00
7,573,000.00
Operating Income
3,999,000.00
4,180,000.00
3,845,000.00
3,787,000.00
4,463,000.00
Net Non Operating Interest Income Expense
-1,296,000.00
-1,135,000.00
-481,000.00
-454,000.00
-486,000.00
Pretax Income
2,611,000.00
2,954,000.00
3,321,000.00
3,295,000.00
4,217,000.00
Tax Provision
470,000.00
546,000.00
683,000.00
616,000.00
972,000.00
Net Income Common Stockholders
2,142,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Diluted NI Available to Com Stockholders
2,142,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Basic EPS
6.38
7.47
8.52
8.67
10.52
Diluted EPS
6.32
7.39
8.44
8.63
10.41
Basic Average Shares
330,071.68
322,658.89
309,477.62
308,898.54
308,487.11
Diluted Average Shares
333,637.83
325,967.65
312,455.23
310,728.93
311,609.10
Total Operating Income as Reported
3,884,000.00
4,066,000.00
3,813,000.00
3,733,000.00
4,818,000.00
Total Expenses
19,141,000.00
17,943,000.00
14,945,000.00
11,742,000.00
10,798,000.00
Net Income from Continuing & Discontinued Operation
2,142,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Normalized Income
2,142,819.99
2,409,815.00
2,638,000.00
2,724,530.80
2,939,707.00
Interest Income
--
27,000.00
5,000.00
--
1,000.00
Interest Expense
--
1,111,000.00
458,000.00
419,000.00
454,000.00
Net Interest Income
-1,296,000.00
-1,135,000.00
-481,000.00
-454,000.00
-486,000.00
EBIT
3,884,000.00
4,065,000.00
3,779,000.00
3,714,000.00
4,671,000.00
EBITDA
7,298,000.00
7,234,000.00
6,051,000.00
5,720,000.00
6,694,000.00
Reconciled Cost of Revenue
5,477,000.00
4,995,000.00
4,776,000.00
3,484,000.00
3,225,000.00
Reconciled Depreciation
3,414,000.00
3,169,000.00
2,272,000.00
2,006,000.00
2,023,000.00
Net Income from Continuing Operation Net Minority Interest
2,142,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Total Unusual Items Excluding Goodwill
-1,000.00
-1,000.00
--
-56,000.00
397,000.00
Total Unusual Items
-1,000.00
-1,000.00
--
-56,000.00
397,000.00
Normalized EBITDA
7,299,000.00
7,235,000.00
6,051,000.00
5,776,000.00
6,297,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-180.01
-185.00
--
-10,469.20
91,707.00
12/31/2020 - 9/20/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRKC.MU Merck KGaA
30.60
0.00%
RIG2.F Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
22.80
-3.55%
LUNA.VI H. Lundbeck A/S
3.7800
+0.80%
LUNB.VI H. Lundbeck A/S
4.4180
+1.05%
MRK.BE Merck KGaA
150.35
-0.79%
I7G0.F Ipsen S.A.
27.00
+0.75%
RGEDF Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
27.77
0.00%
MRK.HA Merck KGaA
150.95
+0.50%
MKGAF Merck KGaA
157.08
-4.99%
0QFP.IL Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
5,040.00
0.00%